WP7: Molecular, ECG, genetic aspects

WP7 Objectives:

• To describe the pharmacokinetic parameters of importance for QT /TdP liability of all study drugs.
• To predict pro-arrhythmia based on the affinity of study drugs for cardiac Na, K and Ca channels (in silico modelling).
• To identify novel electrophysiological parameters for predicting TdP.
• To examine associations between 50,000 genetic polymorphisms in CVD risk genes in cases and controls using a targeted (Illumina) SNP array.To assess the interaction between drug use and 50,000 CVD specific polymorphisms in the case-control studies